Munster PN - Search Results

1

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Messina JL, et al. Among authors: munster pn. Cancer Control. 2008 Jul;15(3):196-201. doi: 10.1177/107327480801500302. Cancer Control. 2008. PMID: 18596671 Free article.

2

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Khan MA, et al. Among authors: munster pn. Cancer Control. 2006 Jul;13(3):211-7. doi: 10.1177/107327480601300308. Cancer Control. 2006. PMID: 16885917 Free article.

3

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. Homsi J, et al. Among authors: munster pn. Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c. Melanoma Res. 2009. PMID: 19434004

4

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. Cancer Res. 2005 May 1;65(9):3815-22. doi: 10.1158/0008-5472.CAN-04-2478. Cancer Res. 2005. PMID: 15867379

5

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Daud AI, et al. Among authors: munster pn. J Clin Oncol. 2008 Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24. J Clin Oncol. 2008. PMID: 19029422 Free PMC article. Clinical Trial.

6

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194. Mol Cancer Ther. 2005. PMID: 16373714

7

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.

Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, Munster PN. Daud AI, et al. Among authors: munster pn. Clin Cancer Res. 2009 Apr 1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318485 Clinical Trial.

8

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. Daud A, et al. Clin Cancer Res. 2005 Apr 15;11(8):3009-16. doi: 10.1158/1078-0432.CCR-04-1722. Clin Cancer Res. 2005. PMID: 15837755 Clinical Trial.

9

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: munster pn. Clin Cancer Res. 2005 Dec 1;11(23):8467-75. doi: 10.1158/1078-0432.CCR-05-1073. Clin Cancer Res. 2005. PMID: 16322310

10

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. Homsi J, et al. Among authors: munster pn. Clin Cancer Res. 2007 Oct 1;13(19):5855-61. doi: 10.1158/1078-0432.CCR-06-2821. Clin Cancer Res. 2007. PMID: 17908979 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters